Education Background
l 2009.09-2015.01 Doctor in East China Normal University; Major: Biomedicine
l 2005.09-2009.07 Bachelor in Linyi University; Majior: Bioscience
Work experience
l 2017.10-Now Assistant professor in Institute of Translational Medicine, Qingdao University
l 2015.07-2017.09 Assistant research fellow in Clinical Transformation Research Institute, Shanghai Central Hospital
Selected Publications:
l P. Shan#, F. Yang#, H. Qi, Y. Hu, S. Zhu, Z. Sun, et al., Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer, Cancer Res 81(15) (2021) 4027-4040.
l P. Shan#, G. Fan#, L. Sun#, J. Q. Liu, W. F. Wang, C. Hu, et al., SIRT1 Functions as a Negative Regulator of Eukaryotic Poly(A)RNA Transport, Current Biology 27(15) (2017) 2271-+.
l L. Sun#, G. Fan#, P. Shan#, X. Qiu, S. Dong, L. Liao, et al., Regulation of energy homeostasis by the ubiquitin-independent REG gamma proteasome, Nature Communications 7 (2016).
l G. Fan#, L. Sun#, P. Shan#, X. Zhang, J. Huan, X. Zhang, et al., Loss of KLF14 triggers centrosome amplification and tumorigenesis, Nature Communications 6 (2015).
l F. Yang, N. Zhao, J. Song, K. Zhu, C. S. Jiang, P. Shan*, et al., Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities, Molecules 24(14) (2019).
l F. Yang#, P. Shan#, N. Zhao, D. Ge, K. Zhu, C. S. Jiang, et al., Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities, Bioorg Med Chem Lett 29(1) (2019) 15-21.
l Z. Sun, Z. Qiu, Z. Wang, H. Chi, P. Shan*, Silencing Ribosomal Protein L22 Promotes Proliferation and Migration, and Inhibits Apoptosis of Gastric Cancer Cells by Regulating the Murine Double Minute 2-Protein 53 (MDM2-p53) Signaling Pathway, Med Sci Monit 27 (2021) e928375.
l D. Wu, J. Yu, X. Song, Y. Ma, P. P. Shan*, H. Zhang*, Diterpenoids from the Roots of Clerodendrum bungei, Rec Nat Prod 16(1) (2022) 27-33.
Research Subjects
l A study of the inhibitory effect of a novel histone deacetylase inhibitor YF452B on breast cancer, form January in 2019 to December in 2021, The National Natural Science Foundation of China
l A study of the mechanism of a novel histone deacetylase inhibitor YF452B on breast cancer, from July in 2019 to June in 2022, The Natural Foundation of Shandong Province
l A study of the Screening of small molecule drugs for targeted therapy of new breast cancer, from December in 2018 to December in 2020, The Postdoctoral Science Foundation of China
l A study of the development and application of breast cancer targeted drug and breast cancer detection kit, from August in 2019 to August in 2021, The Postdoctoral Foundation of Qingdao
